Apoptosis bcl-2 and p53 expression and their relation to tumour stage in non-small cell lung carcinomas (NSCLC)

Cancer Letters

Volumn 116, Issue 2, 1997, Pages 185-189

  Kargi, H Aydanur ^a   Aktaş, Safiye ^a   Sagol, Özgül ^a   Ermete, Sülün ^b   Akpinar, Oya ^a   Akkoçlu, Atilla ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b Department of Pathology   (Turkey)

Author keywords

Apoptosis; Bcl 2; Non small cell lung cancers; p53

Indexed keywords

MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030844315     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00190-0     Document Type: Article

References (16)

1. Hockenbery D. Defining apoptosis (review). Am. J. Pathol. 146:1995;16-19.
2. Kerr J.F.R., Winterford C.M. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 73:1993;2013-2016.
3. Staunton M.J., Gaffney E.O. Tumour type is a determinant of susceptibility to apoptosis. Am. J. Clin. Pathol. 103:1995;300-307.
4. Leonchini L., Vecchio M.T., Megha T. Correlation between apoptotic and proliferative indices in malignant non Hodgkin lymphomas. Am. J. Pathol. 142:1993;755-763.
5. Aihara M., Troung L.P., Dunn J.K.et al. Frequency of apoptotic bodies correlates with Gleason grade in prostate cancer. Hum. Pathol. 25:1994;797-801.
6. Diebold J., Baretton G., Felchner M.et al. Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am. J. Clin. Pathol. 105:1996;341-349.
7. Pazzella F., Turley H., Kuzu I.et al. Bcl-2 protein in non-small cell lung carcinoma. N. Engl. J. Med. 329:1993;690-694.
8. Quinlan D.C., Davidson A.G., Summer C.L.et al. Accumulation of p53 correlates with a poor prognosis in human lung cancer. Cancer Res. 52:1992;4828-4831.
9. Mc Laren R., Kuzu I., Dunnill M.et al. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer. 66:1992;735-738.
10. Brambilla E., Gazzeri S., Moro D., Fromentel C.C., Gouyer V., Yacrot M., Brambilla C. Immunohistochemical study of p53 in human lung carcinomas. Am. J. Pathol. 143:1993;199-210.
11. Viale G., Roncalli M., Grimelius L.et al. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum. Pathol. 26:1995;945-950.
12. Baretton G.B., Diebod J., Christoforis G.et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer. 77:1996;255-264.
13. Mountain C.F. A new international staging system in lung cancer. Chest. 83(Suppl.):1986;2255.
14. Battifora H. Editorial. p53 immunohistochemistry. A word of caution. Hum. Pathol. 25:1994;435-436.
15. Pezzela F., Gatter K. Commentary. What is the value of bcl-2 protein detection for histopathologist? Histopathology. 26:1995;89-93.
16. Bosari S., Moneghini L., Graziani D. Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas and adenocarcinomas. Hum. Pathol. 26:1995;534-540.